Joshi, Kruti
Mao, Lian
Biondi, David M.
Millet, Robert
Funding for this research was provided by:
Janssen Pharmaceuticals
Article History
Received: 19 October 2016
Accepted: 7 January 2018
First Online: 29 January 2018
Ethics approval and consent to participate
: The study was approved by participating ethics committees and institutional review boards (all included in Additional fileInternalRef removed: Table S1), and was conducted in accordance with the ethical principles of the Declaration of Helsinki. Written informed consent was obtained from all subjects prior to study enrollment.
: Not applicable
: KJ and DB are employees of Janssen Scientific Affairs, LLC, and are Johnson & Johnson stockholders. LM is an employee of Janssen Research and Development, LLC, and is a Johnson & Johnson stockholder. RM, an employee of Carolina Behavioral Care, participated in the REACH-OUT study. Janssen Pharmaceuticals markets several antipsychotic medications for the treatment of schizophrenia.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.